东阿阿胶(000423) - 2024 Q3 - 季度业绩预告

Financial Performance - The estimated net profit attributable to shareholders for the first three quarters of 2024 is expected to be between 110,000 and 117,500 million yuan, representing an increase of 40% to 50% compared to the same period last year, which was 78,367.34 million yuan[3]. - The estimated net profit after deducting non-recurring gains and losses is expected to be between 101,495 and 108,995 million yuan, reflecting an increase of 45% to 56% compared to last year's figure of 70,042.39 million yuan[3]. - The estimated basic earnings per share for the first three quarters of 2024 is projected to be between 1.71 and 1.83 yuan per share, compared to 1.22 yuan per share in the same period last year[3]. - For the third quarter of 2024, the estimated net profit attributable to shareholders is expected to be between 36,158 and 43,658 million yuan, indicating an increase of 43% to 73% compared to last year's 25,255.98 million yuan[4]. - The estimated net profit after deducting non-recurring gains and losses for the third quarter is projected to be between 31,537 and 39,037 million yuan, which is an increase of 50% to 85% compared to last year's 21,047.97 million yuan[4]. Business Strategy - The company is focusing on a "dual-driven" growth model combining pharmaceuticals and health consumer products, aiming to enhance brand penetration and consumer conversion[6]. - The company plans to strengthen its core business in traditional Chinese medicine while expanding into new health supplement markets, aiming to become a trusted leader in health supplements[6]. - The company has increased its R&D investment to enhance operational quality and profitability, with a focus on sustainable high-quality development[6]. Cautionary Notes - The financial data presented is preliminary and has not been audited by an accounting firm, with final figures to be confirmed in the Q3 2024 report[7]. - Investors are advised to make cautious decisions and be aware of investment risks due to the preliminary nature of the earnings forecast[7].